JP2021535167A - 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 - Google Patents

哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 Download PDF

Info

Publication number
JP2021535167A
JP2021535167A JP2021511591A JP2021511591A JP2021535167A JP 2021535167 A JP2021535167 A JP 2021535167A JP 2021511591 A JP2021511591 A JP 2021511591A JP 2021511591 A JP2021511591 A JP 2021511591A JP 2021535167 A JP2021535167 A JP 2021535167A
Authority
JP
Japan
Prior art keywords
once
composition
taurolidine
week
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511591A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020047530A5 (https=
JP2021535167A5 (https=
Inventor
ライデンバーグ，ブルース
ディルッチオ，ロバート
Original Assignee
コーメディクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーメディクス・インコーポレーテッド filed Critical コーメディクス・インコーポレーテッド
Publication of JP2021535167A publication Critical patent/JP2021535167A/ja
Publication of JPWO2020047530A5 publication Critical patent/JPWO2020047530A5/ja
Publication of JP2021535167A5 publication Critical patent/JP2021535167A5/ja
Priority to JP2025088837A priority Critical patent/JP2025128194A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021511591A 2018-08-31 2019-09-03 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 Pending JP2021535167A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025088837A JP2025128194A (ja) 2018-08-31 2025-05-28 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725650P 2018-08-31 2018-08-31
US62/725,650 2018-08-31
PCT/US2019/049266 WO2020047530A1 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025088837A Division JP2025128194A (ja) 2018-08-31 2025-05-28 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療

Publications (3)

Publication Number Publication Date
JP2021535167A true JP2021535167A (ja) 2021-12-16
JPWO2020047530A5 JPWO2020047530A5 (https=) 2022-09-07
JP2021535167A5 JP2021535167A5 (https=) 2022-09-07

Family

ID=69643283

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511591A Pending JP2021535167A (ja) 2018-08-31 2019-09-03 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療
JP2025088837A Pending JP2025128194A (ja) 2018-08-31 2025-05-28 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025088837A Pending JP2025128194A (ja) 2018-08-31 2025-05-28 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療

Country Status (7)

Country Link
EP (1) EP3843747A4 (https=)
JP (2) JP2021535167A (https=)
KR (1) KR20210054544A (https=)
CN (1) CN113226325A (https=)
AU (1) AU2019331913B2 (https=)
CA (1) CA3111100A1 (https=)
WO (1) WO2020047530A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363102A (ja) * 2001-04-03 2002-12-18 Ed Geistlich Soehne Ag Fuer Chemische Industrie 新形成細胞の細胞消滅死を誘導する方法
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
JP2003160509A (ja) * 2001-10-19 2003-06-03 Ed Geistlich Soehne Ag Fuer Chemische Industrie 乳癌の治療
JP2013527224A (ja) * 2010-06-01 2013-06-27 ガイストリヒ・ファーマ・アクチェンゲゼルシャフト 経口薬物療法のための方法および組成物
WO2017123635A1 (en) * 2016-01-11 2017-07-20 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2017158570A1 (en) * 2016-03-18 2017-09-21 Geistlich Pharma Ag Method of treating triple negative breast cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
US7151099B2 (en) * 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US7964571B2 (en) * 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
JP2021535163A (ja) * 2018-08-28 2021-12-16 コーメディクス・インコーポレーテッド タウロリジン加水分解産物による神経芽細胞腫治療

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
JP2003515557A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療する方法
JP2002363102A (ja) * 2001-04-03 2002-12-18 Ed Geistlich Soehne Ag Fuer Chemische Industrie 新形成細胞の細胞消滅死を誘導する方法
JP2003160509A (ja) * 2001-10-19 2003-06-03 Ed Geistlich Soehne Ag Fuer Chemische Industrie 乳癌の治療
JP2013527224A (ja) * 2010-06-01 2013-06-27 ガイストリヒ・ファーマ・アクチェンゲゼルシャフト 経口薬物療法のための方法および組成物
WO2017123635A1 (en) * 2016-01-11 2017-07-20 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2017158570A1 (en) * 2016-03-18 2017-09-21 Geistlich Pharma Ag Method of treating triple negative breast cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The Myc oncoprotein as atherapeutic target for human cancer", SEMINARS IN CANCER BIOLOGY, vol. Volume 16,Issue 4, JPN6023035704, 2006, pages 318 - 330, ISSN: 0005357517 *

Also Published As

Publication number Publication date
JP2025128194A (ja) 2025-09-02
EP3843747A4 (en) 2022-12-28
CN113226325A (zh) 2021-08-06
CA3111100A1 (en) 2020-03-05
AU2019331913B2 (en) 2025-06-26
WO2020047530A1 (en) 2020-03-05
AU2019331913A1 (en) 2021-04-29
KR20210054544A (ko) 2021-05-13
EP3843747A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
JP2015078247A (ja) 放射線療法と併用して肺癌の治療に有用なラパマイシン含有高分子ナノ粒子静脈注射用抗癌組成物
KR20040058199A (ko) 폴리 양이온성 폴리머 및 음전하를 띠는 약리학적 활성화합물을 포함하는 제어 방출 약물 전달 조성물
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
Naraharisetti et al. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
JP2021535163A5 (https=)
KR102789553B1 (ko) 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
JP2021535167A (ja) 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
EP3405194B1 (en) A temporary inhibitor of p53 in combination with an anticancer agent for use in the preventing or reducing cancer relapse
RU2270706C2 (ru) Способ комбинированного лечения больных немелкоклеточным раком легкого iii стадии
JP7530351B2 (ja) 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
Zhang et al. polypeptide-based micelles for
Aktaş et al. Neuroblastoma-targeted Anticancer Drug Delivery
Cui et al. Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model
KR20250154513A (ko) 췌장암 치료용 약물 조합
JPWO2020047113A5 (https=)
JPH1081631A (ja) 癌転移または再発抑制剤
JP2023108999A (ja) 抗がん剤含有シート
JP2021535167A5 (https=)
WO2001000240A2 (en) Antitumor compound
JPWO2020047530A5 (https=)
HK1070581A (en) Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250129